Rare and inherited disease at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
125 organizations at ESGCT 2026 present work in rare and inherited disease, led by universities and research institutes. Between them they bring 558 presentations to the program. Most represented: Hannover Medical School, SR-Tiget and University College London. As of Oct 16, 2026.
Format
Top represented
Showing 1–1 of 125 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
Hannover Medical School Hannover, Germany | |
Medical university and hospital with research on AAV and lentiviral vectors, stem cell gene therapy and virus-specific T-cell therapy. | Chair Tue Oct 27 9:00am–10:45am EDUCATION SESSION 1a - Expanding the delivery possibilities by the design of new vectors for gene therapy Vectors and delivery (AAV, lentiviral, LNP) Workshop Tue Oct 27 9:30am–10:45am Adeno-associated virus (AAV) vectors – Insights into strategies for overcoming limitations in host-vector interactions Vectors and delivery (AAV, lentiviral, LNP) Chair Tue Oct 27 11:15am–1:00pm EDUCATION SESSION 2a - What human trials are teaching us Clinical trials and translation Workshop Tue Oct 27 11:40am–1:00pm Workshop Tue Oct 27 12:05pm–1:00pm Safety evaluations of CGT products in vitro and in vivo Clinical trials and translation Talk Tue Oct 27 6:30pm–7:30pm Cell-based therapy for amyloid pathology in Alzheimer's disease using engineered iPSC-Macs Cell therapies and CAR-T Talk Wed Oct 28 10:00am–10:30am In vivo targeting of hematopoietic stem cells by capsid-engineered AAV vectors Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 11:00am–12:30pm Tailored T-cell therapy for viral infections in immunocompromised patients Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm AAV-mediated delivery of SOD1 and Catalase protects against progressive and noise-induced hearing loss via a minimally invasive approach Poster Wed Oct 28 1:30pm–3:30pm Approaches to enhancing antigen-specific immune responses for advancing the prime-boost vaccination platform Poster Wed Oct 28 1:30pm–3:30pm Cryopreserved hematopoietic organoids for distributed and bioreactor-agnostic immune cell manufacturing Poster Wed Oct 28 1:30pm–3:30pm Development and validation of novel strategies to protect against drug-induced nephrotoxicity Poster Wed Oct 28 1:30pm–3:30pm Development of an iPSC-based high-throughput drug screening in Hereditary Pulmonary Arterial Hypertension Poster Wed Oct 28 1:30pm–3:30pm Engineering human iPSC-derived macrophages to decode antiviral stress and deploy regenerative signals Poster Wed Oct 28 1:30pm–3:30pm Generation of low Immunogenic livers by lentiviral vector-mediated genetic engineering delivered during ex-vivo liver perfusion Poster Wed Oct 28 1:30pm–3:30pm Generation of low immunogenic kidneys by downregulating mhc expression during ex vivo machine perfusion Poster Wed Oct 28 1:30pm–3:30pm HLA-Independent CLR-T Cells Targeting UL18 for Universal HCMV Immunotherapy Poster Wed Oct 28 1:30pm–3:30pm Human iPSC-derived macrophages retain functional stability after bronchoscopic lung delivery and enable non-invasive tracking Poster Wed Oct 28 1:30pm–3:30pm LNP-mediated DNA delivery achieves sustained Factor VIII expression in hemophilia A mice Poster Wed Oct 28 1:30pm–3:30pm LNP-mediated base editing reduces hepatic iron overload and modifies fibrosis- and HCC-associated gene expression in HFE-related hemochromatosis mice Poster Wed Oct 28 1:30pm–3:30pm Lipid nanoparticle-based approach for efficient prime editing and intravascular genetic repair of PAH disease-specific mutations Poster Wed Oct 28 1:30pm–3:30pm Scalable manufacturing of cryopreserved human iPSC-derived immunomodulatory macrophages for cell-based therapy of liver fibrosis Poster Wed Oct 28 1:30pm–3:30pm Self-assembling palmitoylated siRNA mediates efficient pulmonary RNAi treatment via inhalation Poster Wed Oct 28 1:30pm–3:30pm Single cell RNAseq-guided identification of a BKV protein VP1- and HLA-C*07:02-restricted TCR for personalized gene-engineered T cell therapy Poster Wed Oct 28 1:30pm–3:30pm Single-cell sequencing reveals antigen-specific T-cell expansion in a patient following adoptive T-cell therapy for progressive multifocal leukoencephalopathy Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm Systematic evaluation of tetraspanins for cargo engineering of MSC-derived extracellular vesicles Poster Wed Oct 28 1:30pm–3:30pm TCR-engineered T cells for HCMV treatment in immunocompromised patients Poster Wed Oct 28 1:30pm–3:30pm Vector-associated acute myeloid leukemia 16 years after gene therapy Talk Wed Oct 28 4:00pm–5:30pm Fit to serve - adapting biological nanoparticles by capsid engineering Vectors and delivery (AAV, lentiviral, LNP) Talk Thu Oct 29 9:30am–10:30am Clinical Proof-of-Concept for In Vivo Base Editing in PI*ZZ Alpha-1 Antitrypsin Deficiency: Results from the YOLT-202 Phase I/II Trial Gene and epigenome editingClinical trials and translation Poster Thu Oct 29 2:00pm–4:00pm A Novel Generation of AAV Vectors to Combat Liver Fibrosis and Improve Liver Transplantation Poster Thu Oct 29 2:00pm–4:00pm AAV-mediated auditory neuron protection (BRIDGE-BDNF): a promising approach for improved cochlear implant performance Poster Thu Oct 29 2:00pm–4:00pm Comparing ex vivo and in vivo performance of receptor binding mutants of adeno-associated virus vectors Poster Thu Oct 29 2:00pm–4:00pm Continuous generation of functional human iPSC-derived NK cells in a scalable hematopoietic organoid system Poster Thu Oct 29 2:00pm–4:00pm Designer lentiviral vectors for precision cell engineering Poster Thu Oct 29 2:00pm–4:00pm Dual T cell-tropic adeno-associated virus vectors platform for generating sustained CAR-T cells in vivo Poster Thu Oct 29 2:00pm–4:00pm Engineering sustainable CAR expression in iPSC and iPSC-derived NK cells through optimized vector and promoter design Poster Thu Oct 29 2:00pm–4:00pm FLT3L and SR1 Regulate Development and Immunostimulatory Function of Human PSC-Derived Dendritic Cells Poster Thu Oct 29 2:00pm–4:00pm Generation of designer regulatory T cells for improved transplantation Poster Thu Oct 29 2:00pm–4:00pm Genetically engineered T cells for targeted depletion of alloreactive B and T cells in solid organ transplantation – CORAT-Ts Poster Thu Oct 29 2:00pm–4:00pm Modeling clonal evolution in human HSPCs to predict insertional mutagenesis following gene therapy Poster Thu Oct 29 2:00pm–4:00pm Novel AAV9-based capsid variants combining immune-modulating features and muscle-tropism Poster Thu Oct 29 2:00pm–4:00pm Pan-cancer CD176-targeting armored CAR-Ts mediate specific elimination of malignant cells from different hematological and solid cancer entities Poster Thu Oct 29 2:00pm–4:00pm Single-cell RNA-seq unveils new immortalization markers of retroviral vector transformed mHSPCs Poster Thu Oct 29 2:00pm–4:00pm Single-cell profiling-guided development of CAR and TRUCK-like NK cell therapies for gynecological malignancies Poster Thu Oct 29 2:00pm–4:00pm Synthetic iPSC-derived macrophages programmed to convert tumor antigen recognition into phagocytosis and cytokine-driven reprogramming Poster Thu Oct 29 2:00pm–4:00pm Targeting Fibroblast Activation Protein through CAR immunotherapy for molecular image-guided cardiac repair Talk Thu Oct 29 4:00pm–6:00pm Machine learning–guided engineering of AAV2 vectors for selective outer hair cell targeting in the inner ear Vectors and delivery (AAV, lentiviral, LNP) Chair Thu Oct 29 6:30pm–7:30pm SESSION 10: Enabling technologies Manufacturing, CMC and access |
Instantly find 20 buyers in rare and inherited disease
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction